Fojo T - Search Results

1

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Burotto M, Manasanch EE, Wilkerson J, Fojo T. Burotto M, et al. Among authors: fojo t. Oncologist. 2015 Apr;20(4):400-10. doi: 10.1634/theoncologist.2014-0154. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795635 Free PMC article.

2

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

Wilkerson J, Fojo T. Wilkerson J, et al. Among authors: fojo t. Cancer J. 2009 Sep-Oct;15(5):379-85. doi: 10.1097/PPO.0b013e3181bef8cd. Cancer J. 2009. PMID: 19826357 Review.

3

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.

Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T. Burotto M, et al. Among authors: fojo t. PLoS One. 2014 May 5;9(5):e96316. doi: 10.1371/journal.pone.0096316. eCollection 2014. PLoS One. 2014. PMID: 24796484 Free PMC article. Clinical Trial.

4

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.

Burotto M, Edgerly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Bates S, Balasubramaniam S, Fojo T. Burotto M, et al. Among authors: fojo t. Oncologist. 2015 Jul;20(7):725-6. doi: 10.1634/theoncologist.2015-0104. Epub 2015 Jun 3. Oncologist. 2015. PMID: 26040622 Free PMC article. Clinical Trial.

5

A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.

Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T. Burotto M, et al. Among authors: fojo t. Oncologist. 2017 Aug;22(8):888-e84. doi: 10.1634/theoncologist.2017-0211. Epub 2017 Jul 5. Oncologist. 2017. PMID: 28679644 Free PMC article. Clinical Trial.

6

Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.

Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Vidaurre T, et al. Among authors: fojo t. Cancer J. 2009 Sep-Oct;15(5):366-73. doi: 10.1097/PPO.0b013e3181b9d37b. Cancer J. 2009. PMID: 19826355 Free PMC article. Review.

7

Non-inferiority trials: why oncologists must remain wary.

Burotto M, Prasad V, Fojo T. Burotto M, et al. Among authors: fojo t. Lancet Oncol. 2015 Apr;16(4):364-6. doi: 10.1016/S1470-2045(15)70129-4. Lancet Oncol. 2015. PMID: 25846084 No abstract available.

8

Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.

Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Jawed I, et al. Among authors: fojo t. JAMA Oncol. 2015 Sep;1(6):787-95. doi: 10.1001/jamaoncol.2015.1790. JAMA Oncol. 2015. PMID: 26181239

9

Mitosis is not a key target of microtubule agents in patient tumors.

Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Komlodi-Pasztor E, et al. Among authors: fojo t. Nat Rev Clin Oncol. 2011 Feb 1;8(4):244-50. doi: 10.1038/nrclinonc.2010.228. Nat Rev Clin Oncol. 2011. PMID: 21283127 Review.

10

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T. O'Sullivan C, et al. Among authors: fojo t. J Clin Endocrinol Metab. 2014 Apr;99(4):1291-7. doi: 10.1210/jc.2013-2298. Epub 2014 Jan 1. J Clin Endocrinol Metab. 2014. PMID: 24423320 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters